Sectoral Asset Management Inc lowered its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 6.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 333,341 shares of the medical device company’s stock after selling 24,000 shares during the period. DexCom comprises about 2.7% of Sectoral Asset Management Inc’s holdings, making the stock its 15th largest holding. Sectoral Asset Management Inc owned approximately 0.39% of DexCom worth $24,384,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Advisor Group Inc. lifted its stake in DexCom by 104.9% during the second quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock worth $119,000 after purchasing an additional 837 shares during the last quarter. Edmond DE Rothschild Holding S.A. bought a new stake in shares of DexCom in the 1st quarter valued at about $164,000. IFP Advisors Inc lifted its stake in shares of DexCom by 30.5% in the 2nd quarter. IFP Advisors Inc now owns 2,431 shares of the medical device company’s stock valued at $178,000 after acquiring an additional 568 shares during the last quarter. Independent Portfolio Consultants Inc. lifted its stake in shares of DexCom by 0.4% in the 2nd quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock valued at $183,000 after acquiring an additional 9 shares during the last quarter. Finally, Brighton Jones LLC bought a new stake in shares of DexCom in the 1st quarter valued at about $204,000.

COPYRIGHT VIOLATION NOTICE: “DexCom, Inc. (DXCM) Shares Sold by Sectoral Asset Management Inc” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.watchlistnews.com/dexcom-inc-dxcm-shares-sold-by-sectoral-asset-management-inc/1601425.html.

DexCom, Inc. (NASDAQ:DXCM) traded up 7.669% on Friday, hitting $48.925. The company’s stock had a trading volume of 9,357,971 shares. DexCom, Inc. has a 12 month low of $45.61 and a 12 month high of $94.24. The firm’s market cap is $4.23 billion. The firm has a 50 day moving average of $72.62 and a 200 day moving average of $73.86.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.07. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. The firm had revenue of $170.60 million during the quarter, compared to the consensus estimate of $166.54 million. During the same quarter in the previous year, the firm posted ($0.24) earnings per share. The company’s revenue was up 24.3% on a year-over-year basis. Equities research analysts forecast that DexCom, Inc. will post ($0.79) earnings per share for the current fiscal year.

In other news, EVP Steven Robert Pacelli sold 1,450 shares of DexCom stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $69.47, for a total transaction of $100,731.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Richard Doubleday sold 1,635 shares of DexCom stock in a transaction that occurred on Wednesday, August 23rd. The shares were sold at an average price of $75.26, for a total transaction of $123,050.10. Following the sale, the executive vice president now directly owns 72,395 shares of the company’s stock, valued at approximately $5,448,447.70. The disclosure for this sale can be found here. Insiders have sold 32,223 shares of company stock valued at $2,285,138 in the last ninety days. Insiders own 1.70% of the company’s stock.

DXCM has been the subject of a number of recent research reports. Oppenheimer Holdings, Inc. set a $92.00 target price on DexCom and gave the company a “buy” rating in a research note on Wednesday, August 2nd. Cowen and Company reissued a “buy” rating and issued a $90.00 target price on shares of DexCom in a research note on Friday, July 14th. BMO Capital Markets reissued a “buy” rating and issued a $105.00 target price on shares of DexCom in a research note on Thursday, July 13th. Piper Jaffray Companies reissued a “buy” rating and issued a $78.00 target price on shares of DexCom in a research note on Wednesday, July 12th. Finally, BidaskClub raised DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday, June 21st. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $72.19.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.